Immunovant, Inc. (IMVT)

NMS – Real Time Price. Currency in USD

29.25

+0.60 (2.09%)

At close: May 13, 2026, 4:00 PM EDT

29.50

+0.25 (0.85%)

After-hours: May 13, 2026, 4:17 PM EDT

06.04.2026

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.

02.04.2026

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

02.04.2026

Immunovant's treatment for eye disease fails late-stage trial

Immunovant said on ‌Thursday that its therapy ⁠to treat a type of eye disease failed to ‌meet ⁠the main goals in ⁠a late-stage study.

15.03.2026

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.

11.03.2026

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.

05.03.2026

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.

17.02.2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

Videos

No Data

There is no data to display

Press releases

17.02.2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

06.02.2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.

05.01.2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

11.12.2025

Immunovant Announces Pricing of $550 Million Common Stock Financing

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company's controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant.

Immunovant, Inc. (IMVT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunovant, Inc. (IMVT)

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant's treatment for eye disease fails late-stage trial

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Videos

No Data

Press releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Announces Pricing of $550 Million Common Stock Financing

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant's treatment for eye disease fails late-stage trial

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Videos

No Data

Press releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Announces Pricing of $550 Million Common Stock Financing

Search stocks

Immunovant, Inc. (IMVT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunovant, Inc. (IMVT)

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant's treatment for eye disease fails late-stage trial

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Videos

No Data

Press releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Announces Pricing of $550 Million Common Stock Financing

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant's treatment for eye disease fails late-stage trial

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Videos

No Data

Press releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Announces Pricing of $550 Million Common Stock Financing